CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

Abstract : BACKGROUND: CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS: We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the contribution of CYP3A4, CYP3A5, and CYP2C8 to everolimus hepatic metabolism using recombinant enzymes. RESULTS: We found no association between CYP3A5 polymorphism and everolimus pharmacokinetics in renal transplant patients. On the other hand, no effect of CYP3A5 polymorphism was observed on the intrinsic clearance of everolimus by human liver microsomes, whereas that of tacrolimus (positive control) was 1.5-fold higher in microsomes carrying the CYP3A5*1 allele than in noncarriers. In vitro data showed that CYP3A4 is a better catalyst of everolimus metabolism than CYP3A5, whereas the opposite was observed for tacrolimus. CONCLUSIONS: This study provides direct and indirect evidence that CYP3A5 genotyping cannot help improve everolimus therapy.
Type de document :
Article dans une revue
Transplantation, Lippincott, Williams & Wilkins, 2011, 91 (6), pp.652-6. 〈10.1097/TP.0b013e31820ae4ac〉
Liste complète des métadonnées

Littérature citée [17 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00542366
Contributeur : Pierre Marquet <>
Soumis le : vendredi 30 mars 2012 - 16:10:19
Dernière modification le : lundi 10 septembre 2018 - 15:38:56
Document(s) archivé(s) le : mardi 13 décembre 2016 - 18:15:14

Fichiers

inserm-00542366_edited.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Nicolas Picard, Koukeb Rouguieg-Malki, Nassim Kamar, Lionel Rostaing, Pierre Marquet. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.. Transplantation, Lippincott, Williams & Wilkins, 2011, 91 (6), pp.652-6. 〈10.1097/TP.0b013e31820ae4ac〉. 〈inserm-00542366〉

Partager

Métriques

Consultations de la notice

210

Téléchargements de fichiers

804